Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation |
| |
| Affiliation: | 1. Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan;2. Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan;3. Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan;4. Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan;5. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan;6. Division of Hematology, Saitama Medical Center, Jichi Medical University, Japan;7. Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;8. Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan;9. Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan;10. Hematology, Osaka City University Graduate School of Medicine, Osaka, Japan;11. Department of Hematology, Tokyo Women''s Medical University, Tokyo, Japan;12. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan;13. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan;14. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan |
| |
| Abstract: | ![]()
Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian population, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after DLI. Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1 year, 2 years, and 5 years were 32% ± 4%, 17% ± 3%, and 7% ± 3%, respectively. Complete remission (CR) at the time of DLI, which was obtained in 8% of the patients, was the strongest predictive factor for survival after DLI. Therefore, long-term survival after DLI was achieved almost exclusively in patients who successfully achieved a CR before DLI, indicating the limited efficacy of DLI in a minority of patients. |
| |
| Keywords: | Acute myeloid leukemia Donor lymphocyte infusion Complete remission |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
